BG108549A - Методи, определящи лекарства на база структура, за идентифициране на d-ala-d-ala лигазни инхибитори като антибактериални лекарства - Google Patents

Методи, определящи лекарства на база структура, за идентифициране на d-ala-d-ala лигазни инхибитори като антибактериални лекарства Download PDF

Info

Publication number: BG108549A
Authority: BG; Bulgaria
Prior art keywords: ala; ligase; inhibitor; potential inhibitor; potential
Prior art date: 2001-06-28

Application number

BG108549A

Other languages

Bulgarian (bg)

English (en)

Inventor

Manuel Navia

Paul Ala

James GRIFFITH

Janid Ali

Carlos FAERMAN

Scott Moe

Andrew MAGEE

Patrick Connelly

Emanuele Perola

Original Assignee

Pliva D.D.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-28

Filing date

2004-01-28

Publication date

2005-02-28

2004-01-28 Application filed by Pliva D.D. filed Critical Pliva D.D.

2005-02-28 Publication of BG108549A publication Critical patent/BG108549A/bg

Links

108020003338 D-alanine-D-alanine ligase Proteins 0.000 title claims abstract description 46
238000000034 method Methods 0.000 title claims description 67
239000000436 ligase inhibitor Substances 0.000 title claims description 5
238000009510 drug design Methods 0.000 title description 3
229940124350 antibacterial drug Drugs 0.000 title 1
239000003112 inhibitor Substances 0.000 claims abstract description 67
230000003993 interaction Effects 0.000 claims abstract description 26
239000000758 substrate Substances 0.000 claims abstract description 12
238000013461 design Methods 0.000 claims abstract description 7
108090000364 Ligases Proteins 0.000 claims description 42
102000003960 Ligases Human genes 0.000 claims description 42
230000001580 bacterial effect Effects 0.000 claims description 26
230000000694 effects Effects 0.000 claims description 15
229910052739 hydrogen Inorganic materials 0.000 claims description 14
239000001257 hydrogen Substances 0.000 claims description 14
150000001413 amino acids Chemical class 0.000 claims description 13
108010056243 alanylalanine Proteins 0.000 claims description 12
DEFJQIDDEAULHB-QWWZWVQMSA-N D-alanyl-D-alanine Chemical compound C[C@@H]([NH3+])C(=O)N[C@H](C)C([O-])=O DEFJQIDDEAULHB-QWWZWVQMSA-N 0.000 claims description 11
241000588724 Escherichia coli Species 0.000 claims description 11
DEFJQIDDEAULHB-UHFFFAOYSA-N N-D-alanyl-D-alanine Natural products CC(N)C(=O)NC(C)C(O)=O DEFJQIDDEAULHB-UHFFFAOYSA-N 0.000 claims description 11
239000000126 substance Substances 0.000 claims description 9
125000004429 atom Chemical group 0.000 claims description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
230000002209 hydrophobic effect Effects 0.000 claims description 4
230000017854 proteolysis Effects 0.000 claims description 4
230000001629 suppression Effects 0.000 claims description 4
230000002194 synthesizing effect Effects 0.000 claims description 4
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 3
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 3
150000001408 amides Chemical class 0.000 claims description 3
229910052799 carbon Inorganic materials 0.000 claims description 3
238000001952 enzyme assay Methods 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
239000001301 oxygen Substances 0.000 claims description 2
125000004430 oxygen atom Chemical group O* 0.000 claims description 2
125000004434 sulfur atom Chemical group 0.000 claims description 2
238000012544 monitoring process Methods 0.000 claims 6
230000002265 prevention Effects 0.000 claims 4
230000002596 correlated effect Effects 0.000 claims 2
230000006641 stabilisation Effects 0.000 claims 2
238000011105 stabilization Methods 0.000 claims 2
229940113306 Ligase inhibitor Drugs 0.000 claims 1
125000004433 nitrogen atom Chemical group N* 0.000 claims 1
102000004190 Enzymes Human genes 0.000 abstract description 49
108090000790 Enzymes Proteins 0.000 abstract description 49
230000008859 change Effects 0.000 abstract description 23
230000005764 inhibitory process Effects 0.000 abstract description 11
238000005457 optimization Methods 0.000 abstract description 7
230000004913 activation Effects 0.000 abstract description 2
150000003384 small molecules Chemical class 0.000 abstract description 2
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 35
150000001875 compounds Chemical class 0.000 description 35
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 16
239000013078 crystal Substances 0.000 description 16
239000000243 solution Substances 0.000 description 16
230000002401 inhibitory effect Effects 0.000 description 14
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 12
239000000370 acceptor Substances 0.000 description 12
239000003446 ligand Substances 0.000 description 12
238000012360 testing method Methods 0.000 description 12
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 11
125000003118 aryl group Chemical group 0.000 description 11
230000008569 process Effects 0.000 description 11
102000004169 proteins and genes Human genes 0.000 description 11
108090000623 proteins and genes Proteins 0.000 description 11
239000002609 medium Substances 0.000 description 9
QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 8
125000001931 aliphatic group Chemical group 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 8
125000001165 hydrophobic group Chemical group 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 7
239000002054 inoculum Substances 0.000 description 7
150000003212 purines Chemical class 0.000 description 7
DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 description 6
DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 description 6
QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 6
239000006137 Luria-Bertani broth Substances 0.000 description 6
230000000844 anti-bacterial effect Effects 0.000 description 6
229960003077 cycloserine Drugs 0.000 description 6
238000003780 insertion Methods 0.000 description 6
230000037431 insertion Effects 0.000 description 6
239000007787 solid Substances 0.000 description 6
PVKSNHVPLWYQGJ-KQYNXXCUSA-N AMP-PNP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)NP(O)(O)=O)[C@@H](O)[C@H]1O PVKSNHVPLWYQGJ-KQYNXXCUSA-N 0.000 description 5
241000894006 Bacteria Species 0.000 description 5
229910019142 PO4 Inorganic materials 0.000 description 5
239000003242 anti bacterial agent Substances 0.000 description 5
229940088710 antibiotic agent Drugs 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
238000000302 molecular modelling Methods 0.000 description 5
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 5
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 5
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
235000021317 phosphate Nutrition 0.000 description 5
239000011550 stock solution Substances 0.000 description 5
238000003556 assay Methods 0.000 description 4
238000002050 diffraction method Methods 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
239000010452 phosphate Substances 0.000 description 4
ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 4
230000004260 plant-type cell wall biogenesis Effects 0.000 description 4
238000012216 screening Methods 0.000 description 4
239000007858 starting material Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
241000606768 Haemophilus influenzae Species 0.000 description 3
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
238000002441 X-ray diffraction Methods 0.000 description 3
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
229960000723 ampicillin Drugs 0.000 description 3
239000000872 buffer Substances 0.000 description 3
210000002421 cell wall Anatomy 0.000 description 3
238000004590 computer program Methods 0.000 description 3
238000010494 dissociation reaction Methods 0.000 description 3
230000005593 dissociations Effects 0.000 description 3
239000003814 drug Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000002532 enzyme inhibitor Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
230000006870 function Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
230000010355 oscillation Effects 0.000 description 3
238000010998 test method Methods 0.000 description 3
238000004448 titration Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
-1 6-substituted 2 aminopurines Chemical class 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
125000000030 D-alanine group Chemical group [H]N([H])[C@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 2
108010016626 Dipeptides Proteins 0.000 description 2
102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
102000006335 Phosphate-Binding Proteins Human genes 0.000 description 2
108010058514 Phosphate-Binding Proteins Proteins 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
102000013009 Pyruvate Kinase Human genes 0.000 description 2
108020005115 Pyruvate Kinase Proteins 0.000 description 2
239000008351 acetate buffer Substances 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
229960005091 chloramphenicol Drugs 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
238000005094 computer simulation Methods 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
238000002447 crystallographic data Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000012634 fragment Substances 0.000 description 2
150000002611 lead compounds Chemical class 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000004807 localization Effects 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
108091005763 multidomain proteins Proteins 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 2
DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 2
229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
239000013598 vector Substances 0.000 description 2
WIIZWVCIJKGZOK-IUCAKERBSA-N 2,2-dichloro-n-[(1s,2s)-1,3-dihydroxy-1-(4-nitrophenyl)propan-2-yl]acetamide Chemical compound ClC(Cl)C(=O)N[C@@H](CO)[C@@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-IUCAKERBSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
BMUDPLZKKRQECS-UHFFFAOYSA-K 3-[18-(2-carboxyethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoic acid iron(3+) hydroxide Chemical compound [OH-].[Fe+3].[N-]1C2=C(C)C(CCC(O)=O)=C1C=C([N-]1)C(CCC(O)=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 BMUDPLZKKRQECS-UHFFFAOYSA-K 0.000 description 1
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
108091006112 ATPases Proteins 0.000 description 1
241000605222 Acidithiobacillus ferrooxidans Species 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
241000187643 Amycolatopsis Species 0.000 description 1
241000893512 Aquifex aeolicus Species 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
241000006382 Bacillus halodurans Species 0.000 description 1
241000588832 Bordetella pertussis Species 0.000 description 1
241000589969 Borreliella burgdorferi Species 0.000 description 1
JNRZNAGCSGWZMY-UHFFFAOYSA-N C(C(=O)C)(=O)OP(=O)=O Chemical compound C(C(=O)C)(=O)OP(=O)=O JNRZNAGCSGWZMY-UHFFFAOYSA-N 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
241001647372 Chlamydia pneumoniae Species 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
241000193163 Clostridioides difficile Species 0.000 description 1
102100032887 Clusterin Human genes 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
241000192091 Deinococcus radiodurans Species 0.000 description 1
241000194033 Enterococcus Species 0.000 description 1
241000194032 Enterococcus faecalis Species 0.000 description 1
241000194031 Enterococcus faecium Species 0.000 description 1
108700037425 Enterococcus faecium VanD Proteins 0.000 description 1
101100372498 Enterococcus faecium vanA gene Proteins 0.000 description 1
241000194030 Enterococcus gallinarum Species 0.000 description 1
241000194029 Enterococcus hirae Species 0.000 description 1
241000193385 Geobacillus stearothermophilus Species 0.000 description 1
241001494297 Geobacter sulfurreducens Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000590002 Helicobacter pylori Species 0.000 description 1
241000405147 Hermes Species 0.000 description 1
101100440171 Homo sapiens CLU gene Proteins 0.000 description 1
101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
241000589242 Legionella pneumophila Species 0.000 description 1
241000192130 Leuconostoc mesenteroides Species 0.000 description 1
MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 1
241000186367 Mycobacterium avium Species 0.000 description 1
241000187480 Mycobacterium smegmatis Species 0.000 description 1
241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
241000588650 Neisseria meningitidis Species 0.000 description 1
241000588677 Neisseria meningitidis serogroup B Species 0.000 description 1
101150026476 PAO1 gene Proteins 0.000 description 1
108010013639 Peptidoglycan Proteins 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
241000320117 Pseudomonas putida KT2440 Species 0.000 description 1
102000004879 Racemases and epimerases Human genes 0.000 description 1
108090001066 Racemases and epimerases Proteins 0.000 description 1
241000606697 Rickettsia prowazekii Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
206010041925 Staphylococcal infections Diseases 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000344863 Staphylococcus aureus subsp. aureus COL Species 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
241000546283 Streptomyces toyocaensis Species 0.000 description 1
241000192581 Synechocystis sp. Species 0.000 description 1
241000204652 Thermotoga Species 0.000 description 1
241000589884 Treponema pallidum Species 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
241000607626 Vibrio cholerae Species 0.000 description 1
241000204362 Xylella fastidiosa Species 0.000 description 1
241001584856 Yersinia pestis CO92 Species 0.000 description 1
241000588902 Zymomonas mobilis Species 0.000 description 1
HFUWQLKNDPPTKF-IMJSIDKUSA-N [(2S)-2-aminopropanoyl] (2S)-2-aminopropaneperoxoate Chemical compound N[C@@H](C)C(=O)OOC([C@@H](N)C)=O HFUWQLKNDPPTKF-IMJSIDKUSA-N 0.000 description 1
241000606834 [Haemophilus] ducreyi Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
150000003838 adenosines Chemical class 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000003385 bacteriostatic effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000003782 beta lactam antibiotic agent Substances 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
238000010876 biochemical test Methods 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229940038705 chlamydia trachomatis Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
238000002288 cocrystallisation Methods 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
238000004891 communication Methods 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
238000012866 crystallographic experiment Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000013480 data collection Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
229940032049 enterococcus faecalis Drugs 0.000 description 1
230000007247 enzymatic mechanism Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
229940125532 enzyme inhibitor Drugs 0.000 description 1
238000002795 fluorescence method Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
239000008103 glucose Substances 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
229940047650 haemophilus influenzae Drugs 0.000 description 1
229940037467 helicobacter pylori Drugs 0.000 description 1
229940109738 hematin Drugs 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000005470 impregnation Methods 0.000 description 1
238000000126 in silico method Methods 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000009878 intermolecular interaction Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
229940115932 legionella pneumophila Drugs 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
238000002493 microarray Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229950006238 nadide Drugs 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
239000002547 new drug Substances 0.000 description 1
229910052762 osmium Inorganic materials 0.000 description 1
SYQBFIAQOQZEGI-UHFFFAOYSA-N osmium atom Chemical compound [Os] SYQBFIAQOQZEGI-UHFFFAOYSA-N 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
229940085991 phosphate ion Drugs 0.000 description 1
229930029653 phosphoenolpyruvate Natural products 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000010399 physical interaction Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
150000003139 primary aliphatic amines Chemical class 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
238000009790 rate-determining step (RDS) Methods 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
239000012925 reference material Substances 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
229940046939 rickettsia prowazekii Drugs 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000005924 transacylation reaction Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229940118696 vibrio cholerae Drugs 0.000 description 1
238000003041 virtual screening Methods 0.000 description 1
239000012224 working solution Substances 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1
239000002132 β-lactam antibiotic Substances 0.000 description 1
229940124586 β-lactam antibiotics Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/93—Ligases (6)

Landscapes

Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Investigating Or Analysing Biological Materials (AREA)

BG108549A 2001-06-28 2004-01-28 Методи, определящи лекарства на база структура, за идентифициране на d-ala-d-ala лигазни инхибитори като антибактериални лекарства BG108549A (bg)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US30167601P	2001-06-28	2001-06-28

Publications (1)

Publication Number	Publication Date
BG108549A true BG108549A (bg)	2005-02-28

Family

ID=23164377

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108549A BG108549A (bg)	2001-06-28	2004-01-28	Методи, определящи лекарства на база структура, за идентифициране на d-ala-d-ala лигазни инхибитори като антибактериални лекарства

Country Status (16)

Country	Link
US (2)	US20030119061A1 (cs)
EP (1)	EP1412516A4 (cs)
CN (1)	CN1268765C (cs)
BG (1)	BG108549A (cs)
BR (1)	BR0211312A (cs)
CA (1)	CA2451837A1 (cs)
CZ (1)	CZ200441A3 (cs)
EA (1)	EA007612B1 (cs)
EE (1)	EE200400044A (cs)
HU (1)	HUP0600158A2 (cs)
IL (1)	IL159539A0 (cs)
MX (1)	MXPA04000157A (cs)
PL (1)	PL367484A1 (cs)
SK (1)	SK282004A3 (cs)
WO (1)	WO2003002063A2 (cs)
YU (1)	YU102403A (cs)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8329060B2 (en) *	2008-10-22	2012-12-11	General Electric Company	Blue-green and green phosphors for lighting applications
US20170314007A1 (en) *	2014-09-30	2017-11-02	China Three Gorges University	Medicament design pocket of ornithine decarboxylase and application of medicament design pocket
CN108504647B (zh) *	2018-03-09	2021-11-05	中山大学	一种dna促旋酶的药物结合口袋及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6251620B1 (en) *	1995-08-30	2001-06-26	Ariad Pharmaceuticals, Inc.	Three dimensional structure of a ZAP tyrosine protein kinase fragment and modeling methods
US6037117A (en) *	1997-01-31	2000-03-14	Smithkline Beecham Corporation	Methods using the Staphylococcus aureus glycyl tRNA synthetase crystalline structure
US6183121B1 (en) *	1997-08-14	2001-02-06	Vertex Pharmaceuticals Inc.	Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets

2002
- 2002-06-28 US US10/186,886 patent/US20030119061A1/en not_active Abandoned
- 2002-06-28 WO PCT/US2002/020465 patent/WO2003002063A2/en not_active Ceased
- 2002-06-28 CN CNB028152700A patent/CN1268765C/zh not_active Expired - Fee Related
- 2002-06-28 CA CA002451837A patent/CA2451837A1/en not_active Abandoned
- 2002-06-28 CZ CZ200441A patent/CZ200441A3/cs unknown
- 2002-06-28 MX MXPA04000157A patent/MXPA04000157A/es unknown
- 2002-06-28 IL IL15953902A patent/IL159539A0/xx unknown
- 2002-06-28 EE EEP200400044A patent/EE200400044A/xx unknown
- 2002-06-28 PL PL02367484A patent/PL367484A1/xx not_active Application Discontinuation
- 2002-06-28 EA EA200400093A patent/EA007612B1/ru unknown
- 2002-06-28 HU HU0600158A patent/HUP0600158A2/hu unknown
- 2002-06-28 BR BR0211312-0A patent/BR0211312A/pt not_active IP Right Cessation
- 2002-06-28 YU YU102403A patent/YU102403A/sh unknown
- 2002-06-28 SK SK28-2004A patent/SK282004A3/sk not_active Application Discontinuation
- 2002-06-28 EP EP02749688A patent/EP1412516A4/en not_active Withdrawn
2004
- 2004-01-28 BG BG108549A patent/BG108549A/bg unknown
2006
- 2006-08-01 US US11/461,678 patent/US20070207512A1/en not_active Abandoned

Also Published As

Publication number	Publication date
PL367484A1 (en)	2005-02-21
CZ200441A3 (cs)	2004-08-18
EP1412516A4 (en)	2004-09-08
EP1412516A2 (en)	2004-04-28
US20070207512A1 (en)	2007-09-06
US20030119061A1 (en)	2003-06-26
WO2003002063A3 (en)	2003-02-20
CA2451837A1 (en)	2003-01-09
HUP0600158A2 (en)	2006-05-29
CN1539020A (zh)	2004-10-20
MXPA04000157A (es)	2005-06-06
CN1268765C (zh)	2006-08-09
EA200400093A1 (ru)	2005-06-30
EA007612B1 (ru)	2006-12-29
IL159539A0 (en)	2004-06-01
WO2003002063A2 (en)	2003-01-09
EE200400044A (et)	2004-10-15
SK282004A3 (sk)	2005-06-02
YU102403A (sh)	2006-08-17
BR0211312A (pt)	2004-07-13

Publication	Publication Date	Title
Srivastava et al.	2005	NAD+-dependent DNA ligase (Rv3014c) from Mycobacterium tuberculosis: crystal structure of the adenylation domain and identification of novel inhibitors
Han et al.	2015	Streptomyces wadayamensis MppP is a pyridoxal 5′-phosphate-dependent l-arginine α-deaminase, γ-hydroxylase in the enduracididine biosynthetic pathway
Burroughs et al.	2013	Structural and functional characterization of MppR, an enduracididine biosynthetic enzyme from streptomyces hygroscopicus: functional diversity in the acetoacetate decarboxylase-like superfamily
Du et al.	2008	Crystal structure and enantiomer selection by D-alanyl carrier protein ligase DltA from Bacillus cereus
Meziane-Cherif et al.	2012	Structural and Functional Characterization of VanG d-Ala: d-Ser Ligase Associated with Vancomycin Resistance in Enterococcus faecalis♦
Michalska et al.	2021	Catalytically impaired TrpA subunit of tryptophan synthase from Chlamydia trachomatis is an allosteric regulator of TrpB
Chen et al.	2006	Structure and kinetics of phosphonopyruvate hydrolase from Voriovorax sp. Pal2: New insight into the divergence of catalysis within the pep mutase/isocitrate lyase superfamily
Scaglione et al.	2017	Structure of the adenylation domain Thr1 involved in the biosynthesis of 4‐chlorothreonine in Streptomyces sp. OH‐5093—protein flexibility and molecular bases of substrate specificity
Priestman et al.	2005	Interaction of phosphonate analogues of the tetrahedral reaction intermediate with 5-enolpyruvylshikimate-3-phosphate synthase in atomic detail
BG108549A (bg)	2005-02-28	Методи, определящи лекарства на база структура, за идентифициране на d-ala-d-ala лигазни инхибитори като антибактериални лекарства
Ramos‐Figueroa et al.	2022	Phosphoenolpyruvate Mutase‐Catalyzed C− P Bond Formation: Mechanistic Ambiguities and Opportunities
Wubben et al.	2010	Kinetic, thermodynamic, and structural insight into the mechanism of phosphopantetheine adenylyltransferase from Mycobacterium tuberculosis
Tranchimand et al.	2011	Treponema denticola PurE is a bacterial AIR carboxylase
Wiltsie et al.	2022	Structural and functional characterization of fosfomycin resistance conferred by FosB from Enterococcus faecium
Shi et al.	2006	Structures of N‐acetylornithine transcarbamoylase from Xanthomonas campestris complexed with substrates and substrate analogs imply mechanisms for substrate binding and catalysis
AU2002320184A1 (en)	2003-03-03	Structure-based drug design methods for identifying d-ala-d-ala ligase inhibitors as antibacterial drugs
Daniel-Ivad et al.	2023	Structure of the oxygen, pyridoxal phosphate-dependent capuramycin biosynthetic protein Cap15
US7747395B2 (en)	2010-06-29	Method of inhibitor design and identification using a 3-D structure of human peptide deformylase
WO2001009154A2 (en)	2001-02-08	USE OF THE CRYSTAL STRUCTURE OF STAPHYLOCOCCUS AUREUS ISOLEUCYL-tRNA SYNTHETASE IN ANTIBIOTIC DESIGN
Zhang	2003	Diversification of structure and catalysis within the haloacid dehalogenase enzyme superfamily
Kemp	2021	Mechanistic Insight into β-Lactamase Catalysis, Inhibitor Design and Resistance
Paranagama	2021	Mechanistic Studies of two tRNA Modification Enzymes and Utilization in Drug Discovery
Panosian	2010	A structural foundation of utilizing Bacillus cereus phosphopentomutase in the synthesis of didanosine
Kim	2004	Molecular engineering of oligomerization and metabolite channeling through a molecular tunnel of carbamoyl phosphate synthetase
Regni	2005	Structural Studies of PMM/PGM from Pseudomonas Aeruginosa